Patents Assigned to VIB VZW
  • Targeted mutant interferon-gamma and uses thereof
    Patent number: 11084859
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 10, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman, Lennart Zabeau
  • Muscle-specific nucleic acid regulatory elements and methods and use thereof
    Patent number: 11072801
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: July 27, 2021
    Assignees: VRIJE Universiteit Brussel, VIB VZW, Universiteit Gent
    Inventors: Thierry Vandendriessche, Marinee Chuah, Pieter De Bleser
  • Galectin-10 antibodies
    Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Membrane span-kinase fusion protein and the uses thereof
    Patent number: 11053300
    Abstract: The disclosure relates to a recombinant membrane span protein complex, comprising (1) a fusion protein, comprising a membrane span protein fused to a kinase domain, preferably a constitutive kinase and (2) a reporter construct comprising a polypeptide, interacting with the membrane span protein, fused to a reporter phosphorylation domain. The disclosure relates further to the uses of such membrane span protein complex for the detection of compounds that interact with the membrane span protein and for the screening and/or detection of inhibitors of the compound-membrane span protein interactions. In a preferred embodiment, the membrane span protein is a G protein coupled receptor (GPCR) and the method is used for the screening and/or detection of inhibitors of the ligand-receptor binding.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 6, 2021
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Samuel Lievens
  • Mutant pores
    Patent number: 11034734
    Abstract: The invention relates to mutant forms of CsgG. The invention also related to analyte detection and characterisation using CsgG.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: June 15, 2021
    Assignees: Oxford Nanopore Technologies Ltd., VIB VZW, Vrije Universiteit Brussel
    Inventors: Stefan Howorka, Han Remaut, Lakmal Jayasinghe, Elizabeth Jayne Wallace, James Anthony Clarke, Richard George Hambley, Jonathan Bankes Pugh
  • NOVEL PROTEIN PORES
    Publication number: 20210147486
    Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 20, 2021
    Applicants: Oxford Nanopore Technologies Limited, VIB VZW, Vrije Universiteit Brussel
    Inventors: Han Remaut, Sander Egbert Van Der Verren, Nani Van Gerven, Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Robert Jordan, John Joseph Kilgour
  • TRANSMEMBRANE PORE CONSISTING OF TWO CSGG PORES
    Publication number: 20210147490
    Abstract: Provided is a method of characterising a polynucleotide using a transmembrane pore, wherein the pore is a double pore comprising a first Csg G pore, or a homologue thereof, and a second CsgG pore, or a homologue thereof.
    Type: Application
    Filed: May 3, 2018
    Publication date: May 20, 2021
    Applicants: Oxford Nanopore Technologies Limited, VIB VZW, Vrije Universiteit Brussel
    Inventors: Lakmal Nishantha Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, Han Remaut
  • TSLP inhibitors
    Patent number: 11001624
    Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 11, 2021
    Assignees: VIB VZW, UniversiteitGent
    Inventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
  • Clec9A binding agents
    Patent number: 11001631
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 11, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley, Anje Cauwels, Sarah Gerlo
  • Bispecific signaling agents and uses thereof
    Patent number: 10988538
    Abstract: The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: April 27, 2021
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Sandra Van Lint, Anje Cauwels
  • Use of 9-tricosene to control
    Patent number: 10986835
    Abstract: The present invention relates to the use of 9-tricosene as a pest control agent against Drosophila suzukii, where in 9-tricosene inhibits mating. The compound 9-tricosene can be used alone or mixed with other compounds in order to control Drosophila suzukii in a more efficient manner. In addition, this present invention provides the use of a dispenser and specific spraying methods with 9-tricosene.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: April 27, 2021
    Assignees: Globachem NV, VIB VZW
    Inventors: Liesbeth Marie Renee Zwarts, Yannick Maria Snellings, Patrick Frans Karel Callaerts, Lieven Denruyter
  • 3-(BENZYLAMINO)-4-(CYCLOHEXYLAMINO)-N-(2-(PIPERAZIN-1-YL)ETHYL)BENZENESULFONAMIDE DERIVATIVES AND RELATED FERROSTATIN-1 ANALOGUES AS CELL DEATH INHIBITORS FOR TREATING E.G. STROKE
    Publication number: 20210094909
    Abstract: The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxytosis for the treatment of stroke, myocardial infarction, diabetes, sepsis, the prevention of transplant rejection, neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, dementia with Lewy bodies and Friedreich's ataxia. The present invention further relates to pharmaceutical compositions of these compounds and discloses methods for making the compounds and the corresponding intermediate.
    Type: Application
    Filed: February 5, 2019
    Publication date: April 1, 2021
    Applicants: VIB VZW, Universiteit Antwerpen, Universiteit Gent
    Inventors: Peter VANDENABEELE, Tom VANDEN BERGHE, Koen AUGUSTYNS, Sam HOFMANS, Pieter VAN DER VEKEN, Lars DEVISSCHER
  • Means and Methods to Treat Inflammatory Diseases
    Publication number: 20210087554
    Abstract: The present application relates to the field of inflammatory diseases, particularly to inflammatory diseases characterized by an M1 macrophage response, even more particularly to sepsis and to Trypanosoma infection. The invention provides substances modulating miR210 expression and/or activity, in particular RNA molecules inhibiting miR210 expression and/or activity and medical uses of these miR210 inhibitors. Methods are disclosed to screen for medicaments for treating sepsis.
    Type: Application
    Filed: October 3, 2017
    Publication date: March 25, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Massimiliano MAZZONE, Anne-Theres HENZE
  • Means and Methods for Treating Bacterial Infections
    Publication number: 20210077563
    Abstract: The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.
    Type: Application
    Filed: May 9, 2018
    Publication date: March 18, 2021
    Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Joost Schymkowitz, Frederic Rousseau
  • Targeted and mutated human-interferon fusion proteins
    Patent number: 10946070
    Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER, UNIVERSITAT OSNABRUCK
    Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
  • Targeting of human interferon antagonists
    Patent number: 10947288
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 16, 2021
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Means and methods for generating complex glycans derived from fungal engineered hosts
    Patent number: 10941418
    Abstract: The present application relates to the field of glyco-engineering, more specifically to glycosylation-engineered fungal cells, more specifically glycosylation-engineered yeast cells, optimized to produce highly homogenous forms of complex N-glycans on recombinant proteins. The invention specifically relates to methods to obtain pharmaceutical compositions comprising recombinant glycoproteins which have homogenous forms of complex N-glycans. In addition, the invention relates to novel pharmaceutical compositions which result from the methods of the invention.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 9, 2021
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico L. M. Callewaert, Bram Laukens
  • METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING NEURAMINIDASE
    Publication number: 20210046176
    Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant neuraminidase (NA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant NA polypeptides.
    Type: Application
    Filed: March 27, 2019
    Publication date: February 18, 2021
    Applicants: SANOFI PASTEUR INC., VIB VZW, UNIVERSITEIT GENT
    Inventors: Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Xavier Saelens, Emma Job
  • Means and methods to treat dystonia
    Patent number: 10881746
    Abstract: The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 5, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R & D
    Inventors: Rose Goodchild, Micheline Grillet
  • Mutations in SPTLC2 gene associated with sensory neuropathy
    Patent number: 10870887
    Abstract: Described are methods and kits for identifying a subject at risk of, or having, a sensory neuropathy related disease, such as sensory neuropathies. In particular, the disclosure is based on the determination of mutations in the SPTLC2 gene causing sensory neuropathies.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: December 22, 2020
    Assignees: VIB VZW, UNIVERSITEIT ANTWERPEN, UNIVERSITY OF ZURICH, MEDICAL UNIVERSITY OF GRAZ
    Inventors: Annelies Rotthier, Vincent Timmerman, Michaela Auer-Grumbach, Thorsten Hornemann